RVMDW (STOCKS)

    Revolution Medicines, Inc. Warrant

    Change: —
    Prev close: —
    Company Information
    Exchange
    XNAS
    Sector
    Industry
    CEO
    Asset Type
    stocks
    Website
    Visit
    Fundamentals
    Market Cap
    Employees
    809
    P/E (TTM)
    P/B (TTM)
    Dividend Yield
    Technical Indicators
    SMA 10
    SMA 20
    SMA 50
    EMA 9
    EMA 21
    RSI
    MACD State
    Recent News

    No recent news found for this ticker.

    Financial Statements
    TTM (Mar 2026)
    Revenues $0.00
    Nonoperating Income/Loss $15.13M
    Operating Expenses $1.39B
    Research and Development $1.13B
    Other Operating Expenses $261.28M
    Operating Income/Loss -$1.39B
    Income/Loss From Continuing Operations After Tax -$1.37B
    Income/Loss From Continuing Operations Before Tax -$1.37B
    Net Income/Loss -$1.37B
    Net Income/Loss Attributable To Noncontrolling Interest $0.00
    Net Income/Loss Attributable To Parent -$1.37B
    Net Income/Loss Available To Common Stockholders, Basic -$1.37B
    Participating Securities, Distributed And Undistributed Earnings/Loss, Basic $0.00
    Preferred Stock Dividends And Other Adjustments $0.00
    Basic Earnings Per Share -$7.10
    Diluted Earnings Per Share -$7.10
    Basic Average Shares 577,384,491
    Diluted Average Shares 577,384,491
    Assets $2.25B
    Current Assets $1.97B
    Noncurrent Assets $285.82M
    Fixed Assets $31.48M
    Intangible Assets $55.80M
    Other Non-current Assets $198.55M
    Liabilities $753.82M
    Current Liabilities $289.60M
    Accounts Payable $80.54M
    Other Current Liabilities $209.06M
    Noncurrent Liabilities $464.22M
    Equity $1.50B
    Equity Attributable To Noncontrolling Interest $0.00
    Equity Attributable To Parent $1.50B
    Liabilities And Equity $2.25B
    Net Cash Flow From Operating Activities -$1.06B
    Net Cash Flow From Operating Activities, Continuing -$1.06B
    Net Cash Flow From Investing Activities $306.62M
    Net Cash Flow From Investing Activities, Continuing $306.62M
    Net Cash Flow From Financing Activities $859.39M
    Net Cash Flow From Financing Activities, Continuing $859.39M
    Net Cash Flow $108.55M
    Net Cash Flow, Continuing $108.55M
    Comprehensive Income/Loss -$1.37B
    Comprehensive Income/Loss Attributable To Noncontrolling Interest $0.00
    Comprehensive Income/Loss Attributable To Parent -$1.37B
    Other Comprehensive Income/Loss -$307.12M